Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PTPRC | P08575 | 1/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2547639 | 0.84 | KDM4E (0.47) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL3004677 | 0.84 | MAPK14 (0.44) | KDM4EALDH1A1HSD17B10CYP1A2PIN1 | |
| SCHEMBL3003054 | 0.82 | PIN1 (0.55) | KDM4ESMN1; SMN2CYP1A2PIN1LMNA | |
| SCHEMBL1340229 | 0.82 | PIN1 (0.52) | PIN1MAPK1MEN1KMT2A | |
| SCHEMBL3009703 | 0.82 | PIN1 (0.50) | SMN1; SMN2PIN1NPC1RAB9AKMT2A | |
| SCHEMBL980858 | 0.82 | KDM4E (0.71) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL9361016 | 0.80 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL3315030 | 0.80 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL80459 | 0.80 | ALOX5 (0.61) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD | |
| SCHEMBL496182 | 0.80 | ALDH1A1 (0.69) | KDM4EALDH1A1SMN1; SMN2HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367696-B2 | Aza-bridged-ring compound | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| CN-101778846-B | 1, 2-diamido-ethylene derivatives as orexin antagonists | ACTELION PHARMACEUTICALS LTD | 2012-11-14 | — | — | CN | disclosed |
| CN-101568536-B | 2-aza-bicyclo[3.1.0]hexane derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-12-28 | — | — | CN | disclosed |
| CN-101790515-A | trans-3-aza-bicyclo[3.1.0]hexane derivatives | ACTELION PHARMACEUTICALS LTD | 2010-07-28 | — | — | CN | disclosed |
| CN-101778846-A | 1, 2-diamido-ethylene derivatives as orexin antagonists | ACTELION PHARMACEUTICALS LTD | 2010-07-14 | — | — | CN | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-04-29 | — | — | US | disclosed |
| CN-101568536-A | 2-aza-bicyclo[3.1.0]hexane derivatives | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-28 | — | — | CN | disclosed |
| EP-2079708-A2 | ACYL AMINOIMIDAZOLES AND ACYL AMINOTHIAZOLES | Bayer HealthCare AG (DE) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008043533-A2 | ACYL AMINOIMIDAZOLES AND ACYL AMINOTHIAZOLES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008043533-A2 | ACYL AMINOIMIDAZOLES AND ACYL AMINOTHIAZOLES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-04-17 | — | — | WO | disclosed |
| EP-0352581-A2 | Ethylene diaminmonoamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1990-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105658-A1 | AZA-BRIDGED-RING COMPOUND | CHRM3, CHRM1, CHRM2 | KDM4E 1245/4885ALDH1A1 2006/4885SMN1; SMN2 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.